Relay Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Relay Therapeutics, Inc. on July 27, 2022, reporting events that occurred on July 25, 2022. The filing addresses corporate governance changes, specifically the appointment of a new director to the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel and governance matters rather than financial performance.
Material Changes
- Board Expansion: The Board of Directors increased its size from seven (7) to eight (8) members.
- New Appointment: Sekar Kathiresan, M.D., was appointed as a Class III director to fill the newly created vacancy.
- Committee Assignment: Dr. Kathiresan was appointed to the Nominating and Corporate Governance Committee.
- Independence: The Board determined Dr. Kathiresan is independent under Nasdaq listing standards and SEC rules.
Guidance, Outlook, and Compensation
There is no financial guidance or outlook provided in this filing. Regarding compensation, Dr. Kathiresan will receive cash and equity in accordance with the Company's Non-Employee Director Compensation Policy. This includes an initial, one-time grant of a non-statutory stock option to purchase 71,881 shares of common stock. The exercise price equals the closing price on the grant date, and the option vests ratably over 36 months contingent on continued service.
Key Facts for Investor Verification
- Verify the independence status of Dr. Sekar Kathiresan relative to the Company's existing business relationships.
- Review the Company's definitive proxy statement filed on April 14, 2022, for details on the Non-Employee Director Compensation Policy.
- Confirm the vesting schedule and exercise price of the 71,881 stock options granted to Dr. Kathiresan.
- Monitor the upcoming press release for the quarter ended June 30, 2022, for the official public announcement of this appointment.